In the Kaplan-Meier survival analysis, patients with positive SLC7A11 expression had significantly lower PFS than patients with negative SLC7A11 expression (95%CI: 46.712~53.119, P<0.05, Figure 3E); in addition, compared with patients with RCC having negative GPX4, patients with positive GPX4 had decreased PFS (95%CI: 46.712~53.119, P<0.05, Figure 3F). Here, GPX4 is linked to renal cell carcinoma.